The First Pharma Fund occupies a niche no other fund in this database does: buying licensed Portuguese community pharmacies, restructuring them, and selling them over an 8-year cycle. It is a closed-end FCR managed by STAG Fund Management and promoted by PharmaForte, marketed as Golden Visa eligible, with subscriptions from €100,000 and a €500,000 threshold for visa applicants, open until January 2027. The thesis is distinctive and the sector is licence-protected, but key economics, including the management and performance fees, have not been published.
Key takeaways
- Closed-end Portuguese FCR with an 8-year term, buying, restructuring and selling licensed community pharmacies; subscriptions run until mid-January 2027.
- Golden Visa eligible per the manager: the fund accepts subscriptions from €100,000, but visa applicants must invest at least €500,000.
- The promoter projects a 52% total return over the fund's life, roughly 6.5% a year on a simple-average basis. A target, not a guarantee.
- Management, performance and subscription fees are not publicly disclosed, and the microsite's "20% hurdle rate" label is ambiguous.
- No published US-investor policy; PFIC treatment is expected by default and QEF reporting is unconfirmed.
What does the First Pharma Fund actually invest in?
Licensed community pharmacies in Portugal, and nothing else. The strategy is to acquire pharmacies, professionalise their management, upgrade operations and technology to lift profitability, then exit through strategic sales before the fund matures. The stated allocation is 100% Portuguese community pharmacies, though a formal portfolio breakdown has not been published.
The sector logic rests on regulation. Portugal caps the number of community pharmacy licences, which limits new competition and protects incumbents' economics. That makes pharmacies closer to licence-protected, cash-flowing operating businesses than to the development projects or early-stage bets that dominate the Golden Visa fund universe. The state giveth and the state can taketh away, of course: pharmacy licensing and medicine-margin rules are set by the Portuguese government, so the same regulation that protects the sector is also its main risk.
Execution sits with two teams. PharmaForte, the promoter, brings pharmacy-market experience through CEO and founder Jorge Forte and COO Paulo Borges. STAG Fund Management, led by co-CEOs António Pereira and Diogo Saraiva de Ponte, is the regulated manager. The fund's microsite lists €16 million as total capital under management, though this may be a target rather than capital actually raised. The promoter projects a 52% estimated return over the 8-year duration, which works out to roughly 6.5% a year on a simple-average basis. Projections are not guarantees, and this fund has no published performance history.
| Term | Detail |
|---|---|
| Structure | Closed-end FCR, Portugal, ISIN PTSFQGIM0005 (Class B) |
| Fund minimum | €100,000 (€500,000 for Golden Visa qualification) |
| Term | 8 years, redemption at term only |
| Subscription deadline | 15 January 2027 per STAG (one aggregator cites 25 January) |
| Projected return | 52% over the fund's life, per the promoter |
What do the fees cost you?
Here the honest answer is: we don't know, and neither will you until you request the fund regulations. Management fee, performance fee, subscription fee, custodian and auditor are all unpublished. That is thinner disclosure than STAG provides for its renewables funds, and it makes the usual arithmetic, entry fee plus management fee compounded over a six-to-seven-year Golden Visa hold, impossible to run from public sources.
The one cost-adjacent number that does appear is odd. The promoter's microsite lists a "20% hurdle rate, minimum performance threshold". A 20% hurdle would be unusually high; the figure may actually describe carried interest charged above some threshold. Either reading changes your net return materially, so this is not a detail to leave ambiguous.
The fund's fee schedule is not publicly disclosed, and the "20% hurdle rate" on the promoter's microsite is ambiguous: it may be a genuine hurdle or a mislabelled carried-interest rate. Before subscribing, obtain the fund regulations and confirm in writing the management fee, performance fee and any subscription charge, and whether the projected 52% return is calculated before or after those costs.
Context helps frame the question. Across this database, management fees typically run around 1.5% to 2% a year. Whether First Pharma sits inside, below or above that band is exactly what the missing documents would tell you.
Liquidity, lock-up and the citizenship timeline
This is a genuine 8-year commitment. The fund is closed-end with no redemption mechanism; your investment is liquidated per fund policy at the end of the cycle, when the restructured pharmacies are sold. Returns are expected to arrive primarily as capital gains at exit rather than as interim distributions, and no formal distribution schedule has been published.
One directory lists a 60-month lock-up, but that likely reflects the Golden Visa's five-year holding requirement rather than any right to redeem at year five. Treat the capital as committed for the full term.
How does that map onto the citizenship timeline? Naturalization currently takes roughly six to seven years in practice, and the visa requires the qualifying investment to be maintained throughout the process. An 8-year term covers that comfortably. The open question is at the other end: the fund's inception date is not published, so the precise liquidation date is unclear, and the term could extend past the point where your immigration process no longer needs the investment. Note also a small discrepancy in the subscription deadline itself: STAG states 15 January 2027, while one aggregator cites 25 January 2027.
What should US citizens check before subscribing?
Whether they can subscribe at all, first. The manager publishes no US-investor policy, directory data records the question as unknown, and one aggregator gates its fund profile behind a non-US-person certification. On the other hand, PharmaForte's own enquiry form lists "American" among selectable nationalities. The signals point in different directions, so get a written answer from the manager before doing anything else.
If US persons are accepted, the tax mechanics follow the familiar script. A non-US closed-end pooled fund is expected to be a PFIC by default for US taxpayers. Whether the fund provides the annual statements needed for a QEF election is unconfirmed, and without them, US investors face a choice between mark-to-market treatment (awkward for a fund with no published NAV frequency) and the punitive default excess-distribution regime. IRA and SDIRA eligibility is not mentioned anywhere in the fund's materials. Model the after-tax outcome with a US tax adviser before subscribing, not after.
How does it compare with other Golden Visa funds?
By sector, it stands alone: no other fund in this database buys pharmacies. The closest structural comparison is the broader group of closed-end private equity funds built on Portuguese operating businesses, where 8-year terms and exit-driven returns are the norm. The €100,000 fund minimum matches the typical entry point in this market, with the €500,000 level relevant only to Golden Visa qualification.
Within STAG's own stable, the contrast is instructive. The manager also runs Vida Fund II, a hospitality repositioning fund, and the Emerald Capital Fund, a renewables vehicle, both with fuller public disclosure than First Pharma currently offers. If a defensive, regulated, cash-flow-driven sector appeals more than development projects or venture bets, the pharmacy thesis is a differentiated entry in the wider universe of Golden Visa funds. What it asks in exchange is comfort with a single sector, a single country, and an exit that depends on selling restructured pharmacies at higher multiples.
What the fund has not published
For completeness, the open items. How much weight each carries depends on your own situation and risk appetite.
- Fees. Management, performance and subscription fees, custodian and auditor are all undisclosed.
- The "20% hurdle rate." Ambiguous labelling on the promoter microsite; needs confirmation in the fund regulations.
- Inception date and capital raised. Neither is confirmed; the €16 million figure may be a target.
- CMVM registration number. The number 2101 comes from an aggregator and has not been verified against the CMVM registry, though the manager confirms CMVM supervision.
- US acceptance and QEF reporting. Both unconfirmed.
- Subscription deadline. 15 versus 25 January 2027, depending on the source.
Next step
If licence-protected operating businesses fit your Golden Visa plan better than venture or development risk, the First Pharma Fund is worth a closer look, with the fee schedule as your first diligence request. Roots can walk you through how it compares with the rest of the database, independently and at your pace. This article is information, not investment, tax or immigration advice; capital is at risk, and past or projected performance is no guarantee of future results.
